Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $244.8252W HIGH $377.54
Volume
781.95 K
Value Traded
500.83 M
Short % Float
2.27%
+2.83%Week
-0.73%1 Month
+5.79%3 Month
+1.48%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
61.80 B
EPS (TTM)
13.75
P/E Ratio
23.54
Ent. Value
70.71 B
Total Shares
190.73 M
Float Shares
189.96 M
Insiders
0.45%
Institutions
100.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
COR Catalyst Timeline
Dated clinical, regulatory and corporate events for Cencora, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cencora, Inc.
8Total events
0Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Event history 7
▲Legal / SettlementCorporate
Dismissal of opioid litigation reduced opioid liability by $102.0 million
▲Runway Guidance UpdateCorporate
Adjusted diluted EPS guidance raised to $17.75-$17.95 for fiscal 2026
Past FDA Catalysts and PDUFA Decisions
How COR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every COR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Krikorian LazarusOfficer (SVP & Chief Accounting Officer) | Sell | -986 15,183 held | $303.18 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in COR for Q2 2026. | ||||
COR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COR ranks across every disease it competes in
Competitive Position is a premium feature
See how COR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOR News
-COR
Oct 2, 2026Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Cencora, Inc. has announced the date for its Fourth Quarter Fiscal 2026 earnings release, scheduled for November 4, 2026. The results will be shared before the market opens, followed by a conference call at 8:30 a.m. ET. Key executives will participate in the call to discuss the financial outcomes.
Read more →-COR
Sep 25, 2026Cencora Elects Robert E. Sanchez to Its Board of Directors
Cencora, Inc. has announced the election of Robert E. Sanchez to its Board of Directors, effective October 1, 2026. Sanchez, who is the Executive Chair of Ryder System, Inc., has a rich background in leadership, having served as CEO and in various roles over two decades. His appointment is expected to enhance the board's expertise.
Read more →-COR
Sep 2, 2026Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
Cencora has launched a new service through Accelerate Pharmacy Solutions to assist health systems in evaluating, building, and scaling cell and gene therapy programs. This initiative aims to enhance operational readiness and execution, ultimately reducing barriers to care and improving patient access to advanced therapies. The service reflects a commitment to advancing healthcare solutions.
Read more →-COR
Aug 5, 2026Cencora Reports Fiscal 2026 Third Quarter Results
Cencora, Inc. reported a 5.1% increase in revenue for its fiscal 2026 third quarter, totaling $84.8 billion. The diluted earnings per share (EPS) rose to $3.94, compared to $3.52 in the same quarter last year. The financial results indicate a positive trend in the company's performance.
Read more →-COR
Jul 1, 2026Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
Cencora has announced the date and time for its earnings release for the third quarter of fiscal 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the earnings report will likely be provided closer to the release date.
Read more →-COR
Jun 17, 2026Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
Cencora has announced the launch of its next-generation Nucleus® solution, which will be tested through a multi-site pilot across specialty physician practices. This initiative aims to enhance the efficiency and effectiveness of specialty care. Further details on the specific features and benefits of the Nucleus® solution were not disclosed.
Read more →-COR
Jun 15, 2026Cencora Announces Samantha Hammock as Chief Human Resources Officer
Cencora has announced the appointment of Samantha Hammock as the new Chief Human Resources Officer. This leadership change is expected to enhance the company's HR strategies and initiatives. Hammock's experience will be pivotal in driving the company's human resource objectives.
Read more →-COR
May 27, 2026Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
Cencora has announced the appointment of Eva Boratto as the new Executive Vice President and Chief Financial Officer. This strategic move aims to enhance the company's leadership team. Further details about her previous experience or specific goals in this role were not provided in the announcement.
Read more →-COR
May 21, 2026Cencora Announces Updated Fiscal Year 2026 Financial Outlook
Cencora has announced an updated financial outlook for the fiscal year 2026. The details of the financial projections and any significant changes have not been disclosed in the article. Further insights into the company's performance and strategic direction may be expected in future communications.
Read more →-COR
May 6, 2026▼ -17.4%on this news
CENCORA REPORTS FISCAL 2026 SECOND QUARTER RESULTS
Cencora, Inc. reported its fiscal 2026 second quarter results, highlighting a 3.8% year-over-year revenue increase to $78.4 billion. The company raised its adjusted diluted earnings per share (EPS) guidance to a range of $17.65 to $17.90, reflecting robust financial performance. Additionally, Cencora is set to repurchase $1 billion in shares by the end of calendar 2026. However, operating expenses surged by 20.9%, and interest expense increased due to financing activities related to a recent acquisition.
Read more →-COR
May 6, 2026▼ -17.4%on this news
Cencora Reports Fiscal 2026 Second Quarter Results
Cencora, Inc. reported strong fiscal 2026 second quarter results, with revenue rising 3.8% to $78.4 billion and diluted earnings per share (EPS) increasing to $8.40. The company raised its adjusted diluted EPS guidance for the fiscal year, reflecting confidence in its operational strategy. However, operating expenses surged due to acquisition costs, and interest expenses also increased.
Read more →-COR
Mar 23, 2026CENCORA TO EXPAND RETINA CONSULTANTS OF AMERICA THROUGH ACQUISITION OF EYESOUTH PARTNERS' RETINA BUSINESS
Cencora, Inc. has signed an agreement to acquire EyeSouth Partners' retina business for $1.1 billion, aiming to enhance its Retina Consultants of America network. The acquisition is projected to be marginally accretive to Cencora's earnings in the first year post-closing. Although the deal is expected to benefit both organizations in delivering quality patient care, it is still subject to regulatory approvals and customary closing conditions. Cencora has reaffirmed its fiscal 2026 financial guidance, although it does not account for the transaction's closure within that timeframe.
Read more →-COR
Mar 17, 2026CENCORA ANNOUNCES FINANCIAL LEADERSHIP TRANSITION
Cencora, Inc. has announced the retirement of James F. Cleary as its Chief Financial Officer, effective June 30, 2026. Cleary has served in this role since November 2018 and will assist in the transition while remaining until the end of 2026. The company has reaffirmed its adjusted diluted EPS guidance for fiscal 2026, projecting between $17.45 and $17.75. Cencora is a major player in the pharmaceutical solutions sector, emphasizing its commitment to market access and health outcomes.
Read more →-COR
Feb 18, 2026COVETRUS AND MWI ANIMAL HEALTH TO MERGE
Cencora and Covetrus have announced a definitive agreement to merge, aimed at creating a comprehensive animal health platform. The merger will enhance accessibility to animal healthcare by combining Covetrus's technology solutions with MWI Animal Health's distribution capabilities. The transaction is valued at $3.5 billion and will see Cencora receive significant equity and cash in the combined entity. However, the deal is subject to customary closing conditions, including regulatory approvals, and Cencora does not anticipate the transaction closing in its fiscal 2026. The merger reflects a strategic move in the evolving animal health sector.
Read more →-COR
Feb 13, 2026CENCORA CLOSES $3.0 BILLION SENIOR NOTES OFFERING
Cencora, Inc. has announced the successful completion of a public offering of $3.0 billion in senior notes. The offering includes various notes maturing from 2029 to 2056, with proceeds intended for debt repayment and general corporate purposes. The offering was facilitated by significant underwriters including Citigroup and J.P. Morgan. This move follows Cencora's recent acquisition of OneOncology and aims to enhance its financial positioning.
Read more →-COR
Feb 10, 2026CENCORA PRICES $500 MILLION 3.950% SENIOR NOTES DUE 2029, $500 MILLION 4.250% SENIOR NOTES DUE 2030, $500 MILLION 4.600% SENIOR NOTES DUE 2033, $1.0 BILLION 4.900% SENIOR NOTES DUE 2036 AND $500 MILLION 5.650% SENIOR NOTES DUE 2056
Cencora, Inc. has announced the pricing of multiple senior notes totaling $3.5 billion, including notes due between 2029 and 2056. The net proceeds will primarily be used to repay amounts under a recent credit agreement related to the acquisition of OneOncology, with any remaining funds allocated for corporate purposes. The offering follows an effective shelf registration statement filed with the SEC. The successful pricing signals investor confidence in Cencora's financial stability and business strategy.
Read more →-COR
Feb 5, 2026▲ +6.7%on this newsshared move
Cencora Reports Fiscal 2026 First Quarter Results
Cencora, Inc. reported a strong financial performance for the first quarter of fiscal 2026, with a revenue increase of 5.5% year-over-year to $85.9 billion. The company raised its adjusted operating income guidance and reaffirmed its adjusted diluted EPS guidance for the fiscal year. The acquisition of OneOncology is expected to enhance its specialty services in cancer care.
Read more →-COR
Feb 4, 2026▼ -8.8%on this newsshared move
CENCORA REPORTS FISCAL 2026 FIRST QUARTER RESULTS
Cencora, Inc. (NYSE: COR) reported strong fiscal Q1 2026 results with a revenue increase of 5.5% year-over-year, reaching $85.9 billion. The company also noted a significant rise in adjusted diluted EPS to $4.08 and raised its adjusted operating income guidance for the fiscal year. The acquisition of OneOncology has positioned Cencora favorably within the healthcare market, particularly in cancer care. However, increased operating expenses and interest costs have raised concerns about profit margins.
Read more →-COR
Jan 22, 2026Cencora Elects Ellen Cooper to Its Board of Directors
Cencora, Inc. has elected Ellen Cooper as an independent director effective January 20, 2026. Cooper, who is the CEO of Lincoln Financial, brings significant experience in risk management and leadership within regulated industries. Her appointment is expected to support Cencora's long-term growth and strategic initiatives.
Read more →-COR
Jan 22, 2026CENCORA ELECTS ELLEN COOPER TO ITS BOARD OF DIRECTORS
Cencora, Inc. has appointed Ellen Cooper to its Board of Directors, effective January 20, 2026. With a distinguished background in risk management and leadership from Lincoln Financial and Goldman Sachs, her expertise is expected to enhance Cencora's ability to support sustainable growth. The Board aims to leverage Ms. Cooper's strategic insights as the company continues its mission in the healthcare sector.
Read more →About Cencora, Inc.
Headquarters1 WEST FIRST AVENUE, CONSHOHOCKEN, PA, 19428
BIOPHARMAWATCH ELITE PLUS
Trade the next COR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime